Jazz market cap is 9.3 billion, 80+% of sales come from Xyrem. Sales growth +/-20%pa. FLML has 45 million shares outstanding. No profit share with Deerfield and Broadfin on SO. Do the maths!
Jazz management notes acquiring/licensing an option. Also, looks like REMS dist patents very weak and in 2016 jazz runs a lot of regulatory risk as there will be important legal decisions as well as clinical risk of successful p3 trial
Sentiment: Strong Buy
You really need to do a google or yahoo search for "Penny Stock 101 org' and signup for their 100% complimentary email newsletter. They consistently bring me winning trade ideas. Just 8 ½ weeks into the 'Fall 2015' season and they've put out a combined total of +1,843% in profit. I am very impressed! Try it out for yourself now
of worthy, light-in-the-loafer immigrants ,particularly those who want to train for
joinng our aggressive band of back door revelers.
Why roost in Fire Island,Key West or Palm Springs,if you can come out in P-Town ?
If FLML is preparing for a "take out",shouldn't CEO Later and Less Anderson be aggressively
trying to boost the stocks's valuation to improve our bargaining position ?
Letting FLML founder could leave lots of money on the table
Why doesn't Deerfield take action ?Is it possible they like treating FLML shareholders like
New CFO to be announced this week. Will take responsibility for IR, better tax planning and preparation for a take out.
...to Infinity and Beyond!
Might require 'extra propulsion' to jettison the massive ego.
Yo Snatcher,how about we launch Later and Less,CEO's underperforming CEO.
Have you ever seen worse IR in your experience
Amen,Brother Cheerio Our dear CEO,Later and Less, has to repair his poor communication
with investors.On the fundamentals,FLML stock should be substantially higher.
Deerfield,Broadfin and Janus should do something about the CEO's failure to support
shareholder values.The control freak CEO might have to walk the plank
Now that the dust has settled from the last CC.
I think it is time you start promoting FLML.
We are way under valued.
Here is why:
Bloxiverz and Vazculep sales are strong and will have a decent tail even if a 3rd player enters the Bloxiverz market. Vazculep is gaining share. Éclat #3 will be on the market this spring and is priced stronger than yourcurrent estimated revenue.
Our P3 for Sodium Oxybate will start soon and we know that is worth a truck load.
Deerfield, Broadfin, Janus and myself are all heavily invested in you and are expecting you to support the stock price and the value of our investment.
Our stock price is essential to any future deals and it is your reputation and leadership that is on the line
With all due respect, it is your responsibility to let everyone know how under valued we are at this level.
If you need help in spreading the word, contact me. I will tell our story louder than you !!
Sentiment: Strong Buy
Yedid Be Gone.
Not that he was helpful, but in his absence, the vacuum is even more pronounced.
a) No slide deck for the quarterly call. With the adjustments, a slide deck and cash flow statement would have been the least they could provide.
b) Under "upcoming events" a notice that the company will be presenting at this week's Jefferies Health Care Conference in London (they did not).
Management's job is, of course, to execute its business plan, but also to give investors reason to own. We think this company is doing the former, but have no doubt it has failed at the latter.